NCT02170701View on ClinicalTrials.gov

BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

289

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

June 30, 2001

Conditions
Venous Thromboembolism
Interventions
DRUG

BIBR 1048

Ascending doses (in mg) given twice daily

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY